Foamix于2003年1月19号在以色列成立。该公司是一家临床阶段制药公司专注于开发和商业化公司专有的泡沫米诺环素治疗痤疮,脓疱疮等皮肤状况。该公司的主导候选产品,fmx101为中度至重...查看全文
牛唐2018-07-28 22:07
$Foamix(FOMX)$ FMX101是外用的minocyline,用于治疗痤疮,预计今年下半年或明年上半年申报NDA,如果获批的话,将是首个获批的米诺环素外用药查看全文
$Foamix(FOMX)$ 8-K - Current report Filed: 2018-11-19 AccNo: 0001178913-18-002991 Size: 50 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 9.01: Financial Statem...
$Foamix(FOMX)$ 内部交易: 2018-11-08,CEO,Domzalski David ,卖出,2062普通股, $4.58
$Foamix(FOMX)$ 内部交易: 2018-11-08,SVP R&D,Stuart Iain ,卖出,683普通股, $4.58
$Foamix(FOMX)$ 8-K - Current report Filed: 2018-11-07 AccNo: 0001178913-18-002852 Size: 2 MBItem 2.02: Results of Operations and Financial ConditionItem 7.01: Regulation FD DisclosureItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Foamix(FOMX)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-11-07 AccNo: 0001178913-18-002850 Size: 3 MB 网页链接
$Foamix(FOMX)$ 美东时间 2018-11-08 盘前 披露财报,预期EPS -0.31 网页链接
$Foamix(FOMX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2018-10-10 AccNo: 0000930413-18-003036 Size: 89 KB 网页链接
$Foamix(FOMX)$ 8-K - Current report Filed: 2018-10-01 AccNo: 0001178913-18-002599 Size: 47 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Foamix(FOMX)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-09-24 AccNo: 0001193125-18-280707 Size: 63 KB 网页链接
$Foamix(FOMX)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-09-24 AccNo: 0001193125-18-280707 Size: 63 KB 网页链接